3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

✍ Scribed by J.R. Hecht; T. Trarbach; E. Jaeger; J. Hainsworth; R.A. Wolff; K. Lloyd; G. Bodoky; M. Borner; D. Laurent; C. Jacques

• Book ID: 118625780
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 58 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)70938-2